Posts for Minerva Neurosciences, Inc. ($NERV)

Showing 1 - 2 of 2 Posts

$NERV

•

Form 10-K

•

2025-02-25

Last updated: 3 months ago

Minerva Neurosciences Q4 2024 Financial Report: Recovery & Challenges Ahead

Explore Minerva Neurosciences' Q4 2024 financial report highlighting a return to profitability, liquidity concerns, and compliance issues. Investment recommendation: Hold.

Biotechnology Financial Recovery FDA Approval Clinical Development Cybersecurity Risk Management

$NERV

•

Form 8-K

•

2025-01-13

Last updated: 5 months ago

Minerva Neurosciences, Inc. 8-K Report: Key Updates for Investors on January 10, 2025

Explore Minerva Neurosciences' latest 8-K report detailing significant updates, stock information, and corporate compliance. Essential insights for investors and stakeholders.

Minerva Neurosciences biotechnology SEC 8-K reporting common stock financial compliance